Erratum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions (Nature Communications (2013) 4, (2218) DOI: 10.1038/ncomms3218);High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions

Nature Communications

Volumn 4, Issue , 2013, Pages

  Nault, Jean Charles ^a,b   Mallet, Maxime ^a,b   Pilati, Camilla ^a,b   Calderaro, Julien ^a,b,c   Bioulac Sage, Paulette ^d,e   Laurent, Christophe ^e   Laurent, Alexis ^c,f   Cherqui, Daniel ^c,g   Balabaud, Charles ^d   Rossi, Jessica Zucman ^a,b,h  

^a Université Paris 13   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d INSERM   (France)

^e HÔPITAL PELLEGRIN   (France)

^f INSERM U955   (France)

^g HÔPITAL PAUL BROUSSE   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CTNNB1 PROTEIN; PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

CANCER; MUTATION; TRANSFORMATION; TUMOR;

ADULT; ARTICLE; FEMALE; GENETIC TRANSCRIPTION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PROMOTER REGION; PROTEIN EXPRESSION; SOMATIC MUTATION;

EID: 84881436148     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3577     Document Type: Erratum

References (32)

1. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012).
2. Nault, J. C. & Zucman-Rossi, J. Genetics of hepatobiliary carcinogenesis. Semin. Liver. Dis. 31, 173-187 (2011).
3. Guichard, C. et al. Integrated analysis of somatic mutations and focal copynumber changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694-698 (2012).
4. Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760-764 (2012).
5. Farazi, P. A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687 (2006). (Pubitemid 44286000)
6. Nault, J. C., Bioulac-Sage, P. & Zucman-Rossi, J. Hepatocellular benign tumorsfrom molecular classification to personalized clinical care. Gastroenterology 144, 888-902 (2013).
7. Zucman-Rossi, J. et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43, 515-524 (2006).
8. Hartmann, D. et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 53, 1608-1617 (2011).
9. Calado, R. T. et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 53, 1600-1607 (2011).
10. Gunes, C. & Rudolph, K. L. The role of telomeres in stem cells and cancer. Cell 152, 390-393 (2013).
11. Farazi, P. A. et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res. 63, 5021-5027 (2003). (Pubitemid 37022640)
12. Lechel, A. et al. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 132, 1465-1475 (2007). (Pubitemid 46627579)
13. Rudolph, K. L., Hartmann, D. & Opitz, O. G. Telomere dysfunction and DNA damage checkpoints in diseases and cancer of the gastrointestinal tract. Gastroenterology 137, 754-762 (2009).
14. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959 (2013).
15. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959-961 (2013).
16. Killela, P. J. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl Acad. Sci. USA 110, 6021-6026 (2013).
17. Nault, J. C. et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145, 176-187 (2013).
18. Cong, Y. S., Wen, J. & Bacchetti, S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Genet. 8, 137-142 (1999). (Pubitemid 29039059)
19. Hoffmeyer, K. et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336, 1549-1554 (2012).
20. Park, J. I. et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460, 66-72 (2009).
21. Zhang, Y., Toh, L., Lau, P. & Wang, X. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/beta-catenin pathway in human cancer. J. Biol. Chem. 287, 32494-32511 (2012).
22. Bioulac-Sage, P. et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 46, 740-748 (2007). (Pubitemid 47436120)
23. Kolquist, K. A. et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat. Genet. 19, 182-186 (1998). (Pubitemid 28248803)
24. Nakayama, J. et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat. Genet. 18, 65-68 (1998). (Pubitemid 28027882)
25. Paterlini-Brechot, P. et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22, 3911-3916 (2003). (Pubitemid 36819664)
26. Sung, W. K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44, 765-769 (2012).
27. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 22, 983-993 (1995).
28. International Consensus Group for Hepatocellular Neoplasia. The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49, 658-664 (2009).
29. Nault, J. C. et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J. Hepatol. 56, 184-191 (2012).
30. Pilati, C. et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp. Med. 208, 1359-1366 (2011).
31. Jeannot, E. et al. Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes 59, 1836-1844 (2010).
32. Boyault, S. et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42-52 (2007). (Pubitemid 46144363)